Lisanti Capital Growth LLC Invests $6.57 Million in Palvella Therapeutics, Inc. $PVLA

Lisanti Capital Growth LLC purchased a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 42,975 shares of the company’s stock, valued at approximately $6,567,000. Palvella Therapeutics comprises approximately 1.4% of Lisanti Capital Growth LLC’s portfolio, making the stock its 21st largest holding.

Several other large investors have also recently modified their holdings of PVLA. BlackRock Inc. bought a new position in Palvella Therapeutics in the 2nd quarter worth about $140,343,000. Summit Partners Public Asset Management LLC increased its stake in Palvella Therapeutics by 1,016.0% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares in the last quarter. Vanguard Group Inc. raised its holdings in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares during the last quarter. State Street Corp raised its holdings in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after buying an additional 283,211 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after buying an additional 280,573 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $149.96 on Thursday. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -31.05 and a beta of -0.17. The business has a 50-day simple moving average of $140.96 and a two-hundred day simple moving average of $123.87. Palvella Therapeutics, Inc. has a fifty-two week low of $46.08 and a fifty-two week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, research analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Analysts Set New Price Targets

PVLA has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Truist Financial set a $207.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $209.14.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.